Societal economic burden and determinants of costs for atopic dermatitis
Abstract Background Atopic dermatitis (AD) is a common inflammatory skin disease while the economic burden of AD by severity is not adequately understood. Objective To estimate the societal economic burden and to identify cost determinants of AD. Methods In this population‐based, controlled cohort s...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-12-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.74 |
| _version_ | 1797987940225253376 |
|---|---|
| author | Gustaf Ortsäter Anna De Geer Alexander Rieem Dun Kirk Geale Ingrid Lindberg Jacob Pontoppidan Thyssen Laura B. vonKobyletzki Alexandra Metsini Dan Henrohn Petra Neregård Amy Cha Joseph C. Cappelleri William Romero Maureen P. Neary |
| author_facet | Gustaf Ortsäter Anna De Geer Alexander Rieem Dun Kirk Geale Ingrid Lindberg Jacob Pontoppidan Thyssen Laura B. vonKobyletzki Alexandra Metsini Dan Henrohn Petra Neregård Amy Cha Joseph C. Cappelleri William Romero Maureen P. Neary |
| author_sort | Gustaf Ortsäter |
| collection | DOAJ |
| description | Abstract Background Atopic dermatitis (AD) is a common inflammatory skin disease while the economic burden of AD by severity is not adequately understood. Objective To estimate the societal economic burden and to identify cost determinants of AD. Methods In this population‐based, controlled cohort study in Sweden, patients with AD were identified through diagnosis codes in primary or secondary care or by dispensed medications using administrative healthcare registers. A reference cohort without AD was randomly selected from the general population. Healthcare costs (primary/secondary care visits and dispensed medication) and indirect costs (care for sick children and long‐term sick leave for adults) were calculated annually. AD patients were stratified by age (paediatric [age < 12], adolescent [12 ≤ age < 18] or adult [age ≥ 18]), and severity (mild‐to‐moderate [M2M] or severe AD) and matched to the reference cohort. Results Compared with controls, the annual mean per‐patient direct healthcare costs in the first year following diagnosis were €941 and €1259 higher in paediatric patients with M2M and severe AD, respectively. In the first year following diagnosis, the mean indirect cost for care of sick children was €69 and €78 higher per patient in M2M and severe AD, respectively. In adolescents with M2M and severe AD, direct healthcare costs were €816 and €1260 higher, respectively. In adults, healthcare costs were €1583 and €2963 higher in patients with M2M and severe AD, respectively and indirect costs were €148 and €263 higher compared with controls. Management of comorbid medical conditions was an important driver of incremental healthcare costs. Total incremental societal economic burden for AD was €351 and €96 million higher in patients with M2M and severe AD, respectively, compared to controls. Conclusion AD is associated with a significant societal economic burden primarily driven by the cost burden of M2M AD due to the high prevalence of this population. Regardless of severity level, management of non‐AD comorbidities is a major driver of total costs. |
| first_indexed | 2024-04-11T07:54:51Z |
| format | Article |
| id | doaj.art-885f76a34f1541309327f1bf780ec2de |
| institution | Directory Open Access Journal |
| issn | 2768-6566 |
| language | English |
| last_indexed | 2024-04-11T07:54:51Z |
| publishDate | 2022-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | JEADV Clinical Practice |
| spelling | doaj.art-885f76a34f1541309327f1bf780ec2de2022-12-22T04:35:57ZengWileyJEADV Clinical Practice2768-65662022-12-011432634310.1002/jvc2.74Societal economic burden and determinants of costs for atopic dermatitisGustaf Ortsäter0Anna De Geer1Alexander Rieem Dun2Kirk Geale3Ingrid Lindberg4Jacob Pontoppidan Thyssen5Laura B. vonKobyletzki6Alexandra Metsini7Dan Henrohn8Petra Neregård9Amy Cha10Joseph C. Cappelleri11William Romero12Maureen P. Neary13Quantify Research Stockholm SwedenPfizer AB Sollentuna SwedenQuantify Research Stockholm SwedenQuantify Research Stockholm SwedenQuantify Research Stockholm SwedenDepartment of Dermatology and Venereology, Bispebjerg Hospital University of Copenhagen Hellerup DenmarkDepartment of Occupational and Environmental Dermatology, Skåne University Hospital Lund University Malmo SwedenInstitute of Medical Sciences University of Örebro Örebro SwedenPfizer AB Sollentuna SwedenPfizer AB Sollentuna SwedenPfizer Inc. New York New York USAPfizer Inc. New York New York USAInflammation & Immunology Pfizer Ltd. London UKPfizer Inc. New York New York USAAbstract Background Atopic dermatitis (AD) is a common inflammatory skin disease while the economic burden of AD by severity is not adequately understood. Objective To estimate the societal economic burden and to identify cost determinants of AD. Methods In this population‐based, controlled cohort study in Sweden, patients with AD were identified through diagnosis codes in primary or secondary care or by dispensed medications using administrative healthcare registers. A reference cohort without AD was randomly selected from the general population. Healthcare costs (primary/secondary care visits and dispensed medication) and indirect costs (care for sick children and long‐term sick leave for adults) were calculated annually. AD patients were stratified by age (paediatric [age < 12], adolescent [12 ≤ age < 18] or adult [age ≥ 18]), and severity (mild‐to‐moderate [M2M] or severe AD) and matched to the reference cohort. Results Compared with controls, the annual mean per‐patient direct healthcare costs in the first year following diagnosis were €941 and €1259 higher in paediatric patients with M2M and severe AD, respectively. In the first year following diagnosis, the mean indirect cost for care of sick children was €69 and €78 higher per patient in M2M and severe AD, respectively. In adolescents with M2M and severe AD, direct healthcare costs were €816 and €1260 higher, respectively. In adults, healthcare costs were €1583 and €2963 higher in patients with M2M and severe AD, respectively and indirect costs were €148 and €263 higher compared with controls. Management of comorbid medical conditions was an important driver of incremental healthcare costs. Total incremental societal economic burden for AD was €351 and €96 million higher in patients with M2M and severe AD, respectively, compared to controls. Conclusion AD is associated with a significant societal economic burden primarily driven by the cost burden of M2M AD due to the high prevalence of this population. Regardless of severity level, management of non‐AD comorbidities is a major driver of total costs.https://doi.org/10.1002/jvc2.74atopic dermatitiseconomic burdeneczemaepidemiologyhealthcare costsindirect costs |
| spellingShingle | Gustaf Ortsäter Anna De Geer Alexander Rieem Dun Kirk Geale Ingrid Lindberg Jacob Pontoppidan Thyssen Laura B. vonKobyletzki Alexandra Metsini Dan Henrohn Petra Neregård Amy Cha Joseph C. Cappelleri William Romero Maureen P. Neary Societal economic burden and determinants of costs for atopic dermatitis JEADV Clinical Practice atopic dermatitis economic burden eczema epidemiology healthcare costs indirect costs |
| title | Societal economic burden and determinants of costs for atopic dermatitis |
| title_full | Societal economic burden and determinants of costs for atopic dermatitis |
| title_fullStr | Societal economic burden and determinants of costs for atopic dermatitis |
| title_full_unstemmed | Societal economic burden and determinants of costs for atopic dermatitis |
| title_short | Societal economic burden and determinants of costs for atopic dermatitis |
| title_sort | societal economic burden and determinants of costs for atopic dermatitis |
| topic | atopic dermatitis economic burden eczema epidemiology healthcare costs indirect costs |
| url | https://doi.org/10.1002/jvc2.74 |
| work_keys_str_mv | AT gustafortsater societaleconomicburdenanddeterminantsofcostsforatopicdermatitis AT annadegeer societaleconomicburdenanddeterminantsofcostsforatopicdermatitis AT alexanderrieemdun societaleconomicburdenanddeterminantsofcostsforatopicdermatitis AT kirkgeale societaleconomicburdenanddeterminantsofcostsforatopicdermatitis AT ingridlindberg societaleconomicburdenanddeterminantsofcostsforatopicdermatitis AT jacobpontoppidanthyssen societaleconomicburdenanddeterminantsofcostsforatopicdermatitis AT laurabvonkobyletzki societaleconomicburdenanddeterminantsofcostsforatopicdermatitis AT alexandrametsini societaleconomicburdenanddeterminantsofcostsforatopicdermatitis AT danhenrohn societaleconomicburdenanddeterminantsofcostsforatopicdermatitis AT petraneregard societaleconomicburdenanddeterminantsofcostsforatopicdermatitis AT amycha societaleconomicburdenanddeterminantsofcostsforatopicdermatitis AT josephccappelleri societaleconomicburdenanddeterminantsofcostsforatopicdermatitis AT williamromero societaleconomicburdenanddeterminantsofcostsforatopicdermatitis AT maureenpneary societaleconomicburdenanddeterminantsofcostsforatopicdermatitis |